Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
NEW YORK, March 04, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015 through September 28, 2015, both dates inclusive (the “Class Period”) of the important March 14, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Esperion Therapeutics investors under the federal securities laws.
To join the Esperion Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-814.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that there was no clear path to approval for ETC-1002, the FDA had encouraged Esperion Therapeutics to initiate a cardiovascular outcomes trial (“CVOT”) and completion of a CVOT could be necessary prior to approval of ETC-1002. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-814.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
